IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

GENEDX, INC.
Petitioner
v.
MYRIAD GENETICS, INC.
Patent Owner

U.S. Patent No. 6,051,379 to Lescallett *et al.*
Issue Date: April 18, 2000
Title: Cancer Susceptibility Mutations of BRCA2

Inter Partes Review No: Unassigned

GENEDX, INC.'S EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

GDX Exhibit #	***Description***
1001	U.S. Patent No. 6,051,379, issued April 18, 2000
1002	Declaration of Dr. Madhuri Hegde, PH.D., FACMG
1003	*Curriculum Vitae* of Dr. Madhuri Hegde, PH.D., FACMG
1004	File History of U.S. Patent No. 6,051,379
1005	Miki, Y., *et al*., "Mutation analysis in the *BRCA2* gene in primary breast cancers," *Nature Genetics* 13: 245-247 (June 13, 1996)
1006	Bowcock, A.M., "Molecular cloning BRCA1: a gene for early onset familial breast and ovarian cancer," *Breast Cancer Research and Treatment* 28: 121-135 (1993)
1007	Hacia, J.G., *et al*., "Detection of heterozygous mutations in *BRCA1* using high density oligonucleotide arrays and two-colour fluorescence analysis," *Nature Genetics* 14: 441-447 (December 14, 1996)
1008	Grompe, M., "The rapid detection of unknown mutations in nucleic acids," *Nature Genetics* 5: 111-117 (1993)
1009	Orita, M., *et al*., "Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms," *PNAS USA* 86: 2766-2770 (1989)
1010	Scharf, S. J., *et al*., "Direct Cloning and Sequence Analysis of Enzymatically Amplified Genomic Sequences," *Science* 233: 1076-1078 (1986)
1011	Weber, B.H.F., *et al*., "A Somatic Truncating Mutation in BRCA2 in a Sporadic Breast Tumor," *Am. J. Hum. Genet.* 59: 962-964 (October 1996)
1012	Lancaster, J.M., *et al*., "*BRCA2* mutations in primary breast and ovarian cancers," *Nature Genetics* 13: 238-240 (June 13, 1996)
1013	Myriad Genetics 2013 Annual Report *downloaded from* http://files.shareholder.com/downloads/MYGN/3399011197x0x699241/42B88246-0E90-4F5C-9697-3DF98027C46D/2013_Annual_Report.pdf
1014	Declaration of Dr. Gregory C. Critchfield, filed December 23, 2009, in *Assoc. for Molecular Pathology v. U.S. Patent & Trademark Office*, No. 09-cv-04515-RWS (S.D.N.Y.)
1015	Declaration of Mark Allan Kay, M.D., Ph.D, filed August 31, 2013, in *University of Utah Research Foundation v. Ambry Genetics Corp*., No. 13-cv-00640-RJS (D.Utah)

GDX Exhibit #	***Description***
1016	Eng, C., *et al*., "Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in *BRCA1," J. Med. Genet.* 38: 824-833 (2001)
1017	Sambrook, J., *et al*., Molecular Cloning, A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, §§ 5.28-5.32, 6.36-6.48, 13.6-13.77, and 14.5-14.21 (1989)
1018	Conner, B.J., *et al*., "Detection of sickle cell β^S-globin allele by hybridization with synthetic oligonucleotides," *PNAS USA* 80: 278-282 (1983)
1019	Teng, D.H.F., *et al*., "Low incidence of *BRCA2* mutations in breast carcinoma and other cancers," *Nature Genetics* 13: 241-244 (June 13, 1996)
1020	Cotton, R.G.H., "Current methods of mutation detection," *Mutation Research* 285: 125-144 (1993)
1021	Handelin, B., *et al*., "Simultaneous Detection of Multiple Point Mutations Using Allele-Specific Oligonucleotides," *Current Protocols in Human Genetics* Suppl. 6: 9.4.1-9.4.8, online publication of May 1, 2001 corresponding to August 1995 print publication
1022	Wooster, R., *et al*., "Localization of a Breast Cancer Susceptibility Gene, *BRCA2*, to Chromosome 13q12-13," *Science* 265: 2088-2090 (1994)
1023	Wooster, R., *et al*., "Identification of the breast cancer susceptibility gene *BRCA2*," *Nature* 378:789-792 (1995)
1024	Schutte, M., *et al*., "Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the *BRCA2* region," *Proc. Natl. Acad. Sci. USA* 92: 5950-5954 (1995)
1025	Alberts, et al. "Molecular Biology of the Cell," 3rd Ed., pp. 98-99, 104-106, 242-243, 292-293, 314-317, 337, 339, 1072-1073, G-5-G-6, G-10, G-17 (1994)
1026	Tavtigian, S.V., *et al*., "The complete *BRCA2* gene and mutations in chromosome 13q-linked kindreds," *Nature Genetics* 12: 333-337 (March 12, 1996)
1027	GenBank Accession No. U43746, "Human breast cancer susceptibility (BRCA2) mRNA, complete cds," modification date of September 3, 1996, available at http://www.ncbi.nlm.nih.gov/nuccore/1161383?sat=13&satkey=6559532 (*last accessed August 6, 2014*)

GDX Exhibit #	***Description***
1028	GenBank Accession No. AAB07223, "BRCA2 [Homo sapiens]," modification date of September 3, 1996, available at http://www.ncbi.nlm.nih.gov/protein/1161384?sat=13&satkey=6559532 (*last accessed August 6, 2014*)
1029	Shattuck-Eidens *et al*., "In Vivo Mutations and Polymorphisms in the 17q-linked Breast and Ovarian Cancer Susceptibility Gene," WO 96/05306 (filed August 11, 1995; published on February 22, 1996)
1030	PACER List of Associated Cases for 14-md-02510, available at https://ecf.utd.uscourts.gov/cgi-bin/qryAscCases.pl?89779 (last accessed on August 15, 2014)

Respectfully submitted,

/Eldora L. Ellison/
Eldora L. Ellison (Reg. No. 39,967)
Lead Attorney for Petitioner GENEDX, Inc.

Date: August 18, 2014
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

1889247_1.DOCX

CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))

The undersigned hereby certifies that the above-captioned "GENEDX, Inc.'s Exhibit List" and Exhibits 1001 – 1030 were served in their entirety on August 18, 2014, upon the following party via FEDEX:

MORGAN LEWIS & BROKIUS, LLP
1111 Pennsylvania Avenue, N.W.
WASHINGTON DC 20004
Patent owner's correspondence address of record for U.S. Patent No. 6,051,379

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

/Eldora L. Ellison/
Eldora L. Ellison (Reg. No. 39,967)
Lead Attorney for Petitioner GENEDX, Inc.

Date: August 18, 2014

1100 New York Avenue, N.W.
Washington, D.C. 20005 - 3934
(202) 371-2600